government organization
National Institute for Health and Care Research
GB
People
Connected researchers
Amir EnglundORCID 0000-0002-2478-209XAnna KolliakouORCID 0000-0003-1234-4129Anthony S. DavidORCID 0000-0003-0967-774XBecky MarsORCID 0000-0002-8132-6920Carmine M. ParianteORCID 0000-0002-9132-5091Caroline CoopeORCID 0000-0001-7803-8760Cathryn M. LewisORCID 0000-0002-8249-8476Chandni HindochaORCID 0000-0003-1692-7401Charles BeckORCID 0000-0002-0967-5333Charles CurtisORCID 0000-0002-2992-1941Clare E. FrenchORCID 0000-0002-6943-7353Craig CollingORCID 0000-0001-5178-0383Craig MorganORCID 0000-0002-1386-2369David GunnellORCID 0000-0002-0829-6470Diego QuattroneORCID 0000-0002-6051-8309Dominic OliverORCID 0000-0002-8920-3407Evangelos VassosORCID 0000-0001-6363-0438Gerome BreenORCID 0000-0003-2053-1792Hannah JonesORCID 0000-0002-5883-9605I OliverORCID 0000-0002-6106-1734Johnny DownsORCID 0000-0002-8061-295XJonathan R. I. ColemanORCID 0000-0002-6759-0944Kate TillingORCID 0000-0002-1010-8926Liam MahedyORCID 0000-0001-5417-6595Luke McGuinnessORCID 0000-0001-8730-9761Marco ColizziORCID 0000-0001-6139-1920Marcus R. MunafòORCID 0000-0002-4049-993XMarta Di FortiORCID 0000-0002-3218-6925Matthew HickmanORCID 0000-0001-9864-459XMichael BloomfieldORCID 0000-0002-1972-4610Michael C O'DonovanORCID 0000-0001-7073-2379Paola DazzanORCID 0000-0002-8427-3617Paolo Fusar-PoliORCID 0000-0003-3582-6788Paul MoranORCID 0000-0002-9257-8699Philip McGuireORCID 0000-0003-4381-0532Robin M. MurrayORCID 0000-0003-0829-0519Robyn E. WoottonORCID 0000-0003-3961-3202Sagnik BhattacharyyaORCID 0000-0002-8688-8025Steph SuddellORCID 0000-0002-5809-1641Val CurranORCID 0000-0001-6041-5214Valeria MondelliORCID 0000-0001-8690-6839
Public evidence
23 connected articles
Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis.2026 · Europe PMCMood instability as a transdiagnostic predictor of cannabis use in attention-deficit/hyperactivity disorder and depression: A natural language processing analysis of electronic health records from 13,025 adolescents.2025 · Europe PMCThe impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies.2024 · Europe PMCExploring the relationship between frequent cannabis use, belief updating under uncertainty and psychotic-like symptoms.2024 · Europe PMCThe Role of Social Deprivation and Cannabis Use in Explaining Variation in the Incidence of Psychotic Disorders: Findings From the EU-GEI Study.2024 · Europe PMCFirst-Episode Psychosis Patients Who Deteriorated in the Premorbid Period Do Not Have Higher Polygenic Risk Scores Than Others: A Cluster Analysis of EU-GEI Data2023 · PubMed Central Open AccessThe association between reasons for first using cannabis, later pattern of use, and risk of first-episode psychosis: the EU-GEI case-control study.2023 · Europe PMCCannabis use and psychotic disorders in diverse settings in the Global South: findings from INTREPID II.2023 · Europe PMCCannabidiol (CBD) as a novel treatment in the early phases of psychosis.2022 · Europe PMCDaily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study.
Registered research
Connected studies
Matched by exact identifiers only. Profile data: OpenAlex.